Retevmo Cost and Affordability
The cost of Retevmo (selpercatinib) can vary significantly based on insurance coverage, geographic location, and the specific dosage and quantity prescribed. As a targeted therapy for certain types of cancer, Retevmo is generally considered a high-cost medication. Pharmaceutical assistance programs may be available to help eligible patients with out-of-pocket expenses.
How much does Retevmo typically cost?
While specific retail prices are not consistently published and fluctuate, Retevmo can cost several thousand dollars per month. For example, a 30-day supply of 80 mg capsules has been listed with prices around $15,000. Actual patient costs will depend on their insurance plan's co-pay, deductible, and co-insurance.
What financial assistance options are available for Retevmo?
Patients prescribed Retevmo may be eligible for financial assistance programs offered by the manufacturer, Eli Lilly and Company. These programs, such as the Lilly Cares Foundation, can provide support to eligible U.S. residents who are uninsured or underinsured, helping to reduce their out-of-pocket costs. Specific eligibility criteria and program details are available through the manufacturer's patient support services.
How does Retevmo's cost compare to other cancer treatments?
Retevmo, like many other targeted therapies and immunotherapies for cancer, falls within a high-cost treatment category. Its price is reflective of the extensive research, development, and clinical trials required for its approval. Comparisons to other cancer drugs can be complex, as pricing is influenced by factors like drug efficacy, patient population, and the disease being treated.
When does Retevmo's patent expire?
Understanding patent expiry dates is crucial for anticipating potential market competition from generic or biosimilar versions, which could impact pricing. DrugPatentWatch.com tracks patent information for many pharmaceuticals, including Retevmo. Information on Retevmo's patent status and expiry can be found on their platform.
Who manufactures Retevmo?
Retevmo is manufactured by Eli Lilly and Company.
What is Retevmo used to treat?
Retevmo is a kinase inhibitor approved for the treatment of specific types of cancers driven by alterations in the RET gene. This includes certain forms of thyroid cancer (medullary thyroid cancer, non-medullary thyroid cancer) and non-small cell lung cancer in patients with RET fusion-positive disease.
Sources:
1. DrugPatentWatch.com